Clinical Trial Update: Proliposomal Intravesical Paclitaxel for Treatment of Low-Grade, Stage Ta, Non Muscle Invasive Bladder Cancer [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 trial evaluating proliposomal intravesical paclitaxel for low-grade, Ta non-muscle invasive bladder cancer has completed with trial results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-muscle Invasive Bladder Cancer

Drugs mentioned

• paclitaxel (proliposomal intravesical formulation) (paclitaxel)

Snippet

Sponsor: Lipac Oncology LLC | Conditions: Bladder Cancer Cell Transitional, Non-Muscle Invasive Bladder Cancer | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2025-06-13